{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=immunohistochemistry+staining+method&page=2", "query": { "intervention": "immunohistochemistry staining method", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=immunohistochemistry+staining+method&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T23:31:26.030Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00551421", "title": "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "pertuzumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "mutation analysis", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-10", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-03-31", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551421" }, { "nct_id": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "biopsy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192815" }, { "nct_id": "NCT01231399", "title": "Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 6, "start_date": "2012-02", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 3, "location_summary": "Duarte, California • South Pasadena, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231399" }, { "nct_id": "NCT01383447", "title": "Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2010-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-08-08", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383447" }, { "nct_id": "NCT00107445", "title": "EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Stage I Endometrial Carcinoma", "Stage I Ovarian Epithelial Cancer", "Stage IA Cervical Cancer", "Stage IB Cervical Cancer", "Stage II Endometrial Carcinoma", "Stage II Ovarian Epithelial Cancer", "Stage IIA Cervical Cancer", "Stage IIB Cervical Cancer", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Ovarian Epithelial Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Ovarian Epithelial Cancer", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "EF5", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2005-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107445" }, { "nct_id": "NCT00389922", "title": "Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "Vinorelbine ditartrate", "type": "DRUG" }, { "name": "comparative genomic hybridization", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-12", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-04-19", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389922" }, { "nct_id": "NCT00425672", "title": "ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "ONTAK", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "protein expression analysis", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2005-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00425672" }, { "nct_id": "NCT00898573", "title": "Lapatinib Resistance in Patients With Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "cell sorting", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-02", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 9, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898573" }, { "nct_id": "NCT01004523", "title": "Study of Tissue and Blood Samples From Patients With Low-Grade Glioma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "loss of heterozygosity analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 135, "start_date": "1995-12", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 38, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Clive, Iowa + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004523" }, { "nct_id": "NCT01497392", "title": "Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dovitinib lactate", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2012-03-29", "completion_date": "2017-02-07", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-09-26T23:31:26.030Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497392" } ] }